Search results
Results from the WOW.Com Content Network
pimobendan – phosphodiesterase 3 inhibitor used to manage heart failure in dogs; pirlimycin – antimicrobial; ponazuril – anticoccidial; praziquantel – treatment of infestations of the tapeworms Dipylidium caninum, Taenia pisiformis, Echinococcus granulosus; prazosin – sympatholytic used in hypertension and abnormal muscle contractions
Pembrolizumab is an immunoglobulin G4, with a variable region against the human PD-1 receptor, a humanized mouse monoclonal [228-L-proline(H10-S>P)]γ4 heavy chain (134-218') disulfide and a humanized mouse monoclonal κ light chain dimer (226-226:229-229)-bisdisulfide. [49] It is recombinantly manufactured in Chinese hamster ovary (CHO) cells.
Pembrolizumab (Keytruda, formerly MK-3475 and lambrolizumab) was developed by Merck and first approved by the Food and Drug Administration in 2014 for the treatment of melanoma. It was later approved for metastatic non-small cell lung cancer and head and neck squamous cell carcinoma .
This pharmacology -related article is a stub. You can help Wikipedia by expanding it.
The United States Food and Drugs Administration is warning pet owners about a common medication given to pets to treat arthritis. The F.D.A. now says that the drug Librela may be associated with ...
Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1 , VEGFR2 and VEGFR3 kinases.
The first checkpoint antibody approved by the FDA was ipilimumab, approved in 2011 for treatment of melanoma. [2] It blocks the immune checkpoint molecule CTLA-4. Clinical trials have also shown some benefits of anti-CTLA-4 therapy on lung cancer or pancreatic cancer, specifically in combination with other drugs. [12] [13]
Durvalumab, [8] sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. [6] It was developed by Medimmune / AstraZeneca . [ 9 ] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 ( PD-L1 ).